San Francisco startup Structure Therapeutics can be working on an oral, the moment-each day GLP-1 drug called GSBR-1290—the drug surpassed Wall Avenue’s anticipations in June whenever a mid-phase analyze confirmed normal weight loss of around six% and it programs to begin An additional mid-stage demo toward the end of the year—that founder an